177 related articles for article (PubMed ID: 35787784)
1. Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an
Shaheen MF; Tse JY; Sokol ES; Masterson M; Bansal P; Rabinowitz I; Tarleton CA; Dobroff AS; Smith TL; Bocklage TJ; Mannakee BK; Gutenkunst RN; Bischoff J; Ness SA; Riedlinger GM; Groisberg R; Pasqualini R; Ganesan S; Arap W
Elife; 2022 Jul; 11():. PubMed ID: 35787784
[TBL] [Abstract][Full Text] [Related]
2. Non-hotspot PIK3CA mutations are more frequent in CLOVES than in common or combined lymphatic malformations.
Brouillard P; Schlögel MJ; Homayun Sepehr N; Helaers R; Queisser A; Fastré E; Boutry S; Schmitz S; Clapuyt P; Hammer F; Dompmartin A; Weitz-Tuoretmaa A; Laranne J; Pasquesoone L; Vilain C; Boon LM; Vikkula M
Orphanet J Rare Dis; 2021 Jun; 16(1):267. PubMed ID: 34112235
[TBL] [Abstract][Full Text] [Related]
3. Linkage of Metabolic Defects to Activated PIK3CA Alleles in Endothelial Cells Derived from Lymphatic Malformation.
Glaser K; Dickie P; Neilson D; Osborn A; Dickie BH
Lymphat Res Biol; 2018 Feb; 16(1):43-55. PubMed ID: 29346025
[TBL] [Abstract][Full Text] [Related]
4. A novel method for isolating lymphatic endothelial cells from lymphatic malformations and detecting PIK3CA somatic mutation in these isolated cells.
Usui H; Tsurusaki Y; Shimbo H; Saitsu H; Harada N; Kitagawa N; Mochizuki K; Masuda M; Kurosawa K; Shinkai M
Surg Today; 2021 Mar; 51(3):439-446. PubMed ID: 32876734
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations.
Blesinger H; Kaulfuß S; Aung T; Schwoch S; Prantl L; Rößler J; Wilting J; Becker J
PLoS One; 2018; 13(7):e0200343. PubMed ID: 29985963
[TBL] [Abstract][Full Text] [Related]
6. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
9. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M; Karakuzulu BB; Uçar GB; Yandım C
Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
[TBL] [Abstract][Full Text] [Related]
10. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations.
Osborn AJ; Dickie P; Neilson DE; Glaser K; Lynch KA; Gupta A; Dickie BH
Hum Mol Genet; 2015 Feb; 24(4):926-38. PubMed ID: 25292196
[TBL] [Abstract][Full Text] [Related]
11. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
[TBL] [Abstract][Full Text] [Related]
14. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Lauer RC; Barry M; Smith TL; Thomas AM; Wu J; Du R; Lee JH; Rao A; Dobroff AS; Arap MA; Nunes DN; Silva IT; Dias-Neto E; Chen I; McCance DJ; Cavenee WK; Pasqualini R; Arap W
Elife; 2023 Jan; 12():. PubMed ID: 36645410
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
17. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
18. A somatic mutation in PIK3CD unravels a novel candidate gene for lymphatic malformation.
Wang S; Wang W; Zhang X; Gui J; Zhang J; Guo Y; Liu Y; Han L; Liu Q; Li Y; Sun N; Liu Z; Du J; Tai J; Ni X
Orphanet J Rare Dis; 2021 May; 16(1):208. PubMed ID: 33964933
[TBL] [Abstract][Full Text] [Related]
19. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
[TBL] [Abstract][Full Text] [Related]
20. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]